Rosetta Capital VII

Asarina Pharma AB (publ) researches and develops pharmaceutical products. Its flagship product is Sepranolone that is in Phase IIb clinical trial to treat premenstrual dysphoric disorder and menstrual migraine. The company was formerly known as Umecrine Mood AB and changed its name to Asarina Pharma AB (publ) in 2016. Asarina Pharma AB (publ) was incorporated in 2005 and is based in Solna, Sweden.

Modus Therapeutics AB is a clinical-stage drug development company based in Stockholm, Sweden, focused on creating pharmaceutical therapies. Founded in 2011, the company is developing sevuparin, a novel drug aimed at treating sickle cell disease, a painful inherited blood disorder that affects millions worldwide. In addition to its primary focus on sickle cell disease, Modus Therapeutics is also exploring the potential of sevuparin for treating conditions associated with severe systemic inflammation, such as sepsis, endotoxemia, and severe malaria, as well as anemia related to chronic inflammation, including kidney diseases. Through its innovative approach, Modus Therapeutics aims to improve patient outcomes and reduce healthcare costs associated with these disorders.

Dilafor AB, a drug development company, develops of pharmaceutical products for obstetric indications. The company offers Tafoxiparin, which is used as an adjuvant therapy to promote cervical ripening and myometrial contractility. It investigates, documents, and exploits the pharmacological properties of low anticoagulant heparin derivatives in the field of obstetrics. The company was founded in 2003 and is based in Solna, Sweden.

NovImmmune is committed to innovation by discovering and developing therapeutic monoclonal antibodies (mAbs) to treat patients suffering from immune-related disorders.

Asarina Pharma AB (publ) researches and develops pharmaceutical products. Its flagship product is Sepranolone that is in Phase IIb clinical trial to treat premenstrual dysphoric disorder and menstrual migraine. The company was formerly known as Umecrine Mood AB and changed its name to Asarina Pharma AB (publ) in 2016. Asarina Pharma AB (publ) was incorporated in 2005 and is based in Solna, Sweden.

Biosergen AS develops variants of nystatin with improved properties. Its pipeline products include S44HP, an antibiotic that is more potent than nystatin against several fungal pathogens; and nystatin analogues produced through manipulation of the nystatin biosynthetic genes.

Aprea Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing cancer therapeutics that target the mutant p53 tumor suppressor protein. The lead product candidate, APR-246, is a first-in-class small molecule p53 reactivator currently in late-stage clinical development for hematologic malignancies, specifically myelodysplastic syndromes and acute myeloid leukemia. Founded in 2006 and headquartered in Boston, Massachusetts, Aprea aims to address significant unmet medical needs in cancer treatment through innovative therapies. The company is primarily backed by KDev Investments AB and other stakeholders, including Östersjöstiftelsen and Praktikerinvest, reflecting a strong investment foundation for its research and development efforts.

MerLion Pharmaceuticals GmbH a pharmaceutical company, develops antibacterial drugs and biological products. The company offers finafloxacin, a fluoroquinolone antibiotic for the treatment of infection. The company was founded in 2008 and is based in Berlin, Germany. As of August 21, 2006, MerLion Pharmaceuticals GmbH operates as a subsidiary of MerLion Pharmaceuticals Pte. Ltd.

EyeSense AG develops ophthalmic diagnostic systems focusing on glucose testing for diabetic patients. They make blood glucose control easier and pain-free through innovative monitoring devices.